Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr 28;112(9):1575-84.
doi: 10.1038/bjc.2015.94. Epub 2015 Mar 24.

Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network

A Smith  1 , S Crouch  1 , S Lax  1 , J Li  1 , D Painter  1 , D Howell  1 , R Patmore  2 , A Jack  3 , E Roman  1
Affiliations

Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network

A Smith et al. Br J Cancer. .

Abstract

Background: Population-based information about cancer occurrence and survival are required to inform clinical practice and research; but for most lymphomas data are lacking.

Methods: Set within a socio-demographically representative UK population of nearly 4 million, lymphoma data (N=5796) are from an established patient cohort.

Results: Incidence, survival (overall and relative) and prevalence estimates for >20 subtypes are presented. With few exceptions, males tended to be diagnosed at younger ages and have significantly (P<0.05) higher incidence rates. Differences were greatest at younger ages: the <15 year male/female rate ratio for all subtypes combined being 2.2 (95% CI 1.3-3.4). These gender differences impacted on prevalence; most subtype estimates being significantly (P<0.05) higher in males than females. Outcome varied widely by subtype; survival of patients with nodular lymphocyte predominant Hodgkin lymphoma approached that of the general population, whereas less than a third of those with other B-cell (e.g., mantle cell) or T-cell (e.g., peripheral-T) lymphomas survived for ≥5 years. No males/female survival differences were detected.

Conclusions: Major strengths of our study include completeness of ascertainment, world-class diagnostics and generalisability. The marked variations demonstrated confirm the requirement for 'real-world' data to inform aetiological hypotheses, health-care planning and the future monitoring of therapeutic changes.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age-specific rates per 100 000 by subtype: Haematological Malignancy Research Network (HMRN) 2004–2012.
Figure 2
Figure 2
Numbers of cases and sex-rate ratios by sub-type and age: Haematological Malignancy Research Network (HMRN) 2004–2012.
Figure 3
Figure 3
Overall and relative survival by subtype: Haematological Malignancy Research Network (HMRN) 2004–2012.
Figure 4
Figure 4
Mature B-cell lymphoma 3, 5, and 10 year prevalence estimates by subtype: Haematological Malignancy Research Network (HMRN) 2004–2012.
See this image and copyright information in PMC

References

    1. Al-Refaie WB, Vickers SM, Zhong W, Parsons H, Rothenberger D, Habermann EB. Cancer trials versus the real world in the United States. Ann Surg. 2011;254:438–442. - PubMed
    1. Armstrong K. Methods in comparative effectiveness research. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:4208–4214. - PMC - PubMed
    1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032. - PMC - PubMed
    1. Cancer Research UK (2006) Cancer Survival Group Strel (v.1.2.7) computer program and life tables for cancer survival analysis.
    1. Crouch S, Smith A, Painter D, Li J, Roman E. Determining disease prevalence from incidence and survival using simulation techniques. Cancer Epidemiol. 2014;38:193–199. - PubMed

Publication types

MeSH terms